IXICO has completed a fundraising
March 2026 — IXICO plc, a specialist in AI-driven neuroimaging analytics, has completed a gross capital raise of US$13.5 million. The funds will be used to support the company’s tech bio strategy, enabling IXICO to partner its platform more broadly and maximize its potential.
IXICO plc is a precision neuroscience company. Its AI-enabled neuroimaging platform supports clinical trials for neurological diseases, including Alzheimer’s and Huntington’s disease, helping biopharmaceutical companies make better and faster decisions in drug development.
Our role in the transaction
Oaklins Cavendish, one of Oaklins’ member firms in the UK, acted as the sole bookrunner and broker for IXICO plc’s US$13.5 million capital raise.
Talk to the deal team
Related deals
Mattina Holding has sold a 5% stake in Gens Aurea via accelerated bookbuild
Mattina Holding S.A. (DVC Partners) has sold a 5% stake in Italian company Gens Aurea S.p.A. through an accelerated bookbuild, raising approximately US$69.96 million.
Learn moreVeremark has completed a secondary share sale
Veremark, the global workplace trust company, has completed an employee and early investor secondary share sale, on the London Stock Exchange’s (LSE) Private Securities Market (PSM), valuing the company at over US$133 million in enterprise value. Crowdcube, Europe’s leading private market liquidity platform, managed the transaction.
Learn moreTandem has completed a voluntary public tender offer for the shares of Compagnia dei Caraibi
Tandem S.r.l. has completed a voluntary public tender offer for 25.99% of the shares in Compagnia dei Caraibi S.p.A.
Learn more